IOB - Delayed Quote DKK
Zealand Pharma A/S (0NZU.IL)
As of 10:58 AM GMT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
76,870.00
342,788.00
103,986.00
108,546.00
192,001.00
Cost of Revenue
21,478.00
19,174.00
--
10,970.00
--
Gross Profit
55,392.00
323,614.00
103,986.00
97,576.00
192,001.00
Operating Expense
1,186,780.00
900,831.00
920,585.00
879,720.00
818,236.00
Operating Income
-1,131,388.00
-577,217.00
-816,599.00
-782,144.00
-626,235.00
Net Non Operating Interest Income Expense
225,788.00
16,343.00
-48,681.00
-7,520.00
-6,620.00
Other Income Expense
--
--
--
30,777.00
-4,068.00
Pretax Income
-1,057,157.00
-708,865.00
-972,041.00
-758,887.00
-673,527.00
Tax Provision
-4,613.00
-5,126.00
-6,431.00
-3,949.00
-4,814.00
Net Income Common Stockholders
-1,052,544.00
-703,739.00
-1,202,135.00
-1,018,149.00
-846,729.00
Diluted NI Available to Com Stockholders
-1,052,544.00
-703,739.00
-1,202,135.00
-1,018,149.00
-846,729.00
Basic EPS
-16.72
-12.44
-26.02
-23.75
-22.07
Diluted EPS
-16.72
-12.44
-26.02
-23.75
-22.07
Basic Average Shares
63,343.10
56,588.59
46,200.15
42,869.40
38,369.70
Diluted Average Shares
63,343.10
56,588.59
46,200.15
42,869.40
38,369.70
Total Operating Income as Reported
-1,126,409.00
-572,238.00
-837,153.00
-784,317.00
-626,235.00
Total Expenses
1,208,258.00
920,005.00
920,585.00
890,690.00
818,236.00
Net Income from Continuing & Discontinued Operation
-1,052,544.00
-703,739.00
-1,202,135.00
-1,018,149.00
-846,729.00
Normalized Income
-936,403.01
-566,455.96
-834,122.71
-749,220.91
-667,554.34
Interest Income
123,911.00
45,324.00
6,542.00
44.00
895.00
Interest Expense
27,968.00
24,888.00
56,455.00
4,091.00
2,895.00
Net Interest Income
225,788.00
16,343.00
-48,681.00
-7,520.00
-6,620.00
EBIT
-1,029,189.00
-683,977.00
-915,586.00
-754,796.00
-670,632.00
EBITDA
-1,001,113.00
-658,891.00
-797,625.00
-711,850.00
-627,940.00
Reconciled Cost of Revenue
21,478.00
19,174.00
--
10,970.00
--
Reconciled Depreciation
28,076.00
25,086.00
117,961.00
42,946.00
42,692.00
Net Income from Continuing Operation Net Minority Interest
-1,052,544.00
-703,739.00
-965,610.00
-754,938.00
-668,713.00
Total Unusual Items Excluding Goodwill
-116,650.00
-138,283.00
-132,363.00
-5,747.00
-1,167.00
Total Unusual Items
-116,650.00
-138,283.00
-132,363.00
-5,747.00
-1,167.00
Normalized EBITDA
-884,463.00
-520,608.00
-665,262.00
-706,103.00
-626,773.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-509.01
-999.96
-875.71
-29.91
-8.34
12/31/2020 - 8/5/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
0NZT.IL UCB SA
181.95
0.00%
87S.F Roivant Sciences Ltd.
10.42
+0.97%
ALCOX.PA Nicox S.A.
0.2435
-1.22%
ROVI.MC Laboratorios Farmaceuticos Rovi, S.A.
65.45
-0.46%
1VT.F Viking Therapeutics, Inc.
64.54
+0.94%
OSE.PA OSE Immunotherapeutics SA
9.98
-0.79%
BION.SW BB Biotech AG Ord
39.00
+0.39%
ORY.MC Oryzon Genomics S.A.
1.5940
-0.62%
1VT.BE Viking Therapeutics Inc
63.94
+0.63%
FENC Fennec Pharmaceuticals Inc.
4.3600
-11.92%